Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

Inclusion criteria

• PDAC FAMILY HISTORY OR PDAC RELATED GENETIC MUTATIONS:
• Age: 50 or older, plus at least one of the following:
• Mutation unknown or absent:
• 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject;
• OR 2+ affected first degree relatives \[(FDR), defined as blood related parents, siblings, or children\]
• Known pathogenic/likely pathogenic (P/LP) mutation in at least one of the following:
• CDKN2A/p16, Peutz-Jeghers syndrome (PJS) serine/threonine kinase 11 (STK11), Hereditary pancreatitis with confirmed protease serine 1 (PRSS1)
• OR 1+ or second degree relative (SDR) with PDAC and a known P/LP mutation in one or more of:
• ATM, BRCA1, BRCA2, PALB2, Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), TP53
• HIGH-RISK OR WORRISOME PANCREATIC CYSTS:
• 18 years of age or greater and meeting Fukuoka worrisome (FW) or Fukuoka high-risk (FHR) criteria
• High risk stigmata:
• Obstructive Jaundice in a patient with cystic lesion of the head of the pancreas
• Enhancing mural nodule ≥ 5 mm
• Main pancreatic duct ≥ 10 mm
• Worrisome features:
• Presence of pancreatic duct stricture, defined as focal pancreatic duct narrowing with upstream duct =\> 6 mm
• Cyst ≥ 3 cm
• Enhancing mural nodule \< 5 mm
• Thickened/Enhancing cyst wall
• Main duct size 5-9 mm
• Pancreatitis
• Lymphadenopathy
• Increased CA 19-9
• Cyst growth rate ≥ 5 mm /2 years

Exclusion criteria

• Is unable to provide informed consent
• Has received a non-autologous bone marrow transplant or has an active hematologic malignancy (i.e., leukemia or lymphoma)
• Current or prior history of PDAC or total pancreatectomy
• Is currently a prison inmate
• Is not able to speak or read English